EGFR and colorectal carcinoma: While EGFR signaling is a central target in metastatic CRC therapy [146,147], ANXA1 may enhance both EGFR activation and stabilization, thereby contributing to cancer immune evasion via the ANXA1/EGFR interaction [42].